M032

BIOLOGICAL2 trials

Sponsors

University of Alabama at Birmingham, M.D. Anderson Cancer Center

Conditions

Anaplastic AstrocytomaGlioblastoma MultiformeGliomaGliosarcoma

Phase 1

Study of Pembrolizumab and M032 (NSC 733972)

RecruitingNCT05084430

University of Alabama at BirminghamAnaplastic Astrocytoma, Glioblastoma Multiforme, Gliosarcoma

Start: 2022-02-25End: 2028-03-01Target: 28Updated: 2026-01-22

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

RecruitingNCT07076498

M.D. Anderson Cancer CenterGlioma

Start: 2026-04-23End: 2031-12-31Target: 20Updated: 2026-09-09

Related Papers

Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.

2023-08-1214 citations